Cytodyn Inc (CYDY)

[Leronlimab4DaWin]

This is Called a PIVOT


CytoDyn’s Leronlimab Prevents Transmission of SHIV in Macaque Study
Results of preclinical study presented today in oral presentation at the 23rd
International AIDS Conference (AIDS 2020) 
VANCOUVER, Washington, July 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc.
(OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage
biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist
with the potential clinical indications for HIV, COVID-19, cancer, GvHD and NASH
announced today the results from a preclinical macaque study evaluating
leronlimab as pre-exposure prophylaxis (PrEP) to prevent sexual HIV
transmission. The study evaluated the impact of a macaque-equivalent dose of
CytoDyn Cut to Neutral From Buy by HC Wainwright & Co.
either 350 mg (once weekly) or 700 mg (bi-monthly) leronlimab on acquisition
CytoDyn Cut to Neutral at HC Wainwright
of infection in a total of 18 animals, and found that the equivalent 700 mg bi-
CytoDyn Announces Execution of Exclusive Agreement with Amer
monthly leronlimab dose completely prevented rectal transmission of Simian-
RTT News: CytoDyn To Supply Leronlimab For Treatment Of COV
Human Immunodeficiency Virus (SHIV) in macaques. These results were
Trials and Tribulations Point to Ways to Save Covid Patients (1)
presented today in an oral presentation titled “CCR5 antibody blockade protects
rhesus macaques from rectal SHIV acquisition" at the 23rd International AIDS
Cellectis Falls After Study Halted Following Patient Death (1)
Conference (AIDS 2020).
“The results reported here in the preclinical macaque model of HIV sexual
Press Releases
transmission support leronlimab as a possible PrEP agent at a time when long-